Paulina Hill

Paulina joined Sanofi Ventures in 2022 as a Partner, with a background in early-stage biotech investing and company building, and currently serves on the boards of Avilar, NextPoint, Normunity, Vrata, and a board observer at Aliada. Prior to joining Sanofi, Paulina was a Principal at Omega Funds where she served as the board director or observer for Scorpion Therapeutics, Arrakis Therapeutics, IFM, and additionally led or co-led Omega’s investments in Theseus (NASDAQ: THRX), Ikena (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina began her career with Polaris Partners and served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Lyra Therapeutics (NASDAQ: LYRA), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics, where she was founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in Chemical Engineering at MIT. While there, Paulina founded the MIT Postdoctoral Association, served as its President, and also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology, and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.